Viridian Therapeutics, Inc./DE Unrealized Gain (Loss) on Investments
Viridian Therapeutics, Inc./DE (VRDN) reported Unrealized Gain (Loss) on Investments of -$300.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2025-03-03
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for the quarter ending 2021-12-31 was -$95.00K.
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for the quarter ending 2021-09-30 was $9.40K.
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for the quarter ending 2021-06-30 was $9.00K.
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for the quarter ending 2021-03-31 was -$13.00K.
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for fiscal 2024 was -$300.00K, a 142.86% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for fiscal 2023 was $700.00K.
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for fiscal 2022 was -$200.00K.
- Viridian Therapeutics, Inc./DE unrealized gain (loss) on investments for fiscal 2021 was -$100.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$300.00K 10-K · filed 2025-03-03 | |||
| 2023-12-31 | $700.00K 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$200.00K 10-K · filed 2025-03-03 | |||
| 2021-12-31 | -$95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$85.60K derived: sum of 2 quarters · filed 2024-02-27 | -$76.60K derived: sum of 3 quarters · filed 2024-02-27 | -$100.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $9.40K 10-Q · filed 2021-11-05 | $18.40K derived: sum of 2 quarters · filed 2021-11-05 | -$5.00K 10-Q · filed 2021-11-05 | -$2.60K derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-06-30 | $9.00K 10-Q · filed 2021-08-12 | -$4.00K 10-Q · filed 2021-08-12 | -$12.00K derived: sum of 3 quarters · filed 2022-03-11 | -$12.00K derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-03-31 | -$13.00K 10-Q · filed 2021-05-07 | -$21.00K derived: sum of 2 quarters · filed 2022-03-11 | -$21.00K derived: sum of 3 quarters · filed 2022-03-11 | -$21.00K derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$8.00K derived: sum of 2 quarters · filed 2022-03-11 | -$8.00K derived: sum of 3 quarters · filed 2022-03-11 | -$8.00K 10-K · filed 2022-03-11 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | -$3.00K derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | -$3.00K derived: sum of 3 quarters · filed 2021-08-12 | -$11.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | -$3.00K derived: sum of 2 quarters · filed 2021-05-07 | -$11.00K derived: sum of 3 quarters · filed 2021-05-07 | -$2.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | -$11.00K derived: sum of 2 quarters · filed 2021-03-26 | -$2.00K derived: sum of 3 quarters · filed 2021-03-26 | $3.00K 10-K · filed 2021-03-26 |
| 2019-09-30 | -$8.00K 10-Q · filed 2020-11-12 | $1.00K derived: sum of 2 quarters · filed 2020-11-12 | $6.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $9.00K 10-Q · filed 2020-08-05 | $14.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $5.00K 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | -$3.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |